Nanobiosym Selected As One Of The Top Growth Stage Ventures By The ‘Unreasonable’ Group

Monday, 18 March 2019

 “The reasonable man adapts himself to the world; the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man [& woman].”
— George Bernard Shaw

Cambridge, MA, Monday, March 18, 2019 — After a rigorous and highly competitive selection process involving hundreds of companies across the globe, Nanobiosym^® has been selected as one of the world’s top 15 growth-stage ventures that will be backed by the Unreasonable Group as entrepreneurs who are bending history in the right direction. Unreasonable FUTURE is a bold, multi-year initiative that will bring together disruptive innovators and entrepreneurs to design a future in which people and technology work side-by-side to solve global challenges and unlock human potential everywhere.

Nanobiosym^® has harnessed the new science of Nanobiophysics to build and commercialize its (recently FDA-authorized) XPRIZE-winning Gene-RADAR^® platform to bring real-time personalized, mobilized diagnostic information about one’s own health to 8 billion consumers, including the 4 billion who today lack access to centralized lab infrastructure.

“Unreasonable FUTURE is bringing together a hand-picked portfolio of entrepreneurs leveraging advanced technologies to ensure future generations thrive in the new economy,” Daniel Epstein, founder and CEO of Unreasonable Groupsaid. “It’s an honor to have the opportunity to support these outstanding ventures to help design a future that will work for everyone.”

The portfolio includes entrepreneurs using disruptive technologies to maximize human potential in the workplace of tomorrow. By bringing them together, the goal is to rewrite the narrative of what it means for all humans to thrive in a new, more equitable economy.

“We at Nanobiosym are excited and honored to join this ‘Unreasonable’ group of entrepreneurs who are working to solve some of the world’s most pressing challenges,” said Dr. Anita Goel, MD, Ph.D., Founder, Chairman, and CEO of Nanobiosym. “Through our Gene-RADAR^® platform, our team at Nanobiosym is working to decentralize, personalize, and mobilize the next generation of healthcare delivery by exponentially increasing access to real-time, accurate diagnostics for anyone, anywhere at any time. Our partnership with Unreasonable Group represents another bold step forward in our quest to transform the outdated paradigm of centralized healthcare delivery into a new model where next-generation technology that can ultimately empower the 8 billion people on our planet with real-time access to information about their own health and wellness.”

The first Unreasonable FUTURE program will take place from March 27 - April 7, at a private venue outside of San Jose, California. A full list of selected companies, mentors, and specialists participating in Unreasonable FUTURE can be found here. Additional details about the partnership and program can be found on the website.

 ###

About Unreasonable Group

Unreasonable envisions a world in which the most valuable and influential companies are those solving humanity’s most pressing challenges. Through running worldwide immersive programs for growth-stage entrepreneurs, unique partnerships with multinationals, a globally-oriented private equity fund, an extensive international community of serial business leaders as mentors, and advanced storytelling and media activities, Unreasonable is designed to exclusively support entrepreneurs positioned to bend history in the right direction. Currently, Unreasonable works with 162 entrepreneurs who support the jobs of more than 170,000 people and who are actively impacting the lives of over 260 million individuals across more than 180 countries have raised over $2.3 billion dollars in funding and generated more than $1.8 billion in revenue. For more, visit www.unreasonablegroup.com.

About Nanobiosym^®

Nanobiosym Diagnostics, Inc. (NBSDx) has built and is commercializing its XPRIZE-winning Gene-RADAR^® platform (FDA EUA authorized for its first “app”) to advance applications in personalized precision medicine, global health and pandemic preparedness.

The Nanobiosym Research Institute (NBS) is focused on advancing the new science of Nanobiophysics and harnessing these transformative innovations with novel business models and public-private partnerships to address the United Nations Millennium Sustainable Development Goals and find breakthrough solutions to our planet’s greatest challenges in healthcare, energy, water, and the environment.

About Dr. Anita Goel, MD, Ph.D. — Chairman and CEO of Nanobiosym^®

Dr. Anita Goel, MD, Ph.D., is a world-renowned Nanobiophysics scientist and global entrepreneur. Named by MIT’s Technology Review as one of the world’s “Top TR35 science and technology innovators” and by Scientific American as one of the “Top 100 Most Influential Biotech Visionaries,” Dr. Goel holds a Ph.D. in Physics from Harvard University, an MD from the Harvard-MIT Joint Division of Health Sciences & Technology (HST), and a B.S. in Physics with Honors and Distinction from Stanford University. The recipient of three DARPA Breakthrough Research Awards and the winner of the first XPrize for healthcare, Dr. Goel and Nanobiosym (NBS) have a strong track record of winning and delivering US government and Fortune 500 contracts, including the Galactic Challenge Award (CASIS, NASA, & Elon Musk’s SpaceX), two USAID Grand Challenge Awards, and many other highly competitive peer-reviewed awards from the U.S. DOD, DOE, AFOSR, HHS Therapeutic Discovery Awards, and the NSF. 

Media Contact: Ryan Rudominer, press@nanobiosym.com 

Please add a comment